Chromadex Corp Stock OTC Bulletin Board
Stocks
CDXC
US1710771007
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| Market Cap | 242M 212M 200M 183M 342M 23.18B 344M 2.4B 929M 11.84B 908M 888M 38.06B | P/E 2026 * |
22.8x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 242M 212M 200M 183M 342M 23.18B 344M 2.4B 929M 11.84B 908M 888M 38.06B | EV / Sales 2026 * |
1.82x | EV / Sales 2027 * | 1.56x |
| Free-Float |
70.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Chromadex Corp
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Fried
CEO | Chief Executive Officer | 66 | 2018-05-31 |
Ozan Pamir
DFI | Director of Finance/CFO | 35 | 2024-10-20 |
Mona Rosene
CTO | Chief Tech/Sci/R&D Officer | - | 2020-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Jaksch
CHM | Chairman | 57 | 2018-06-21 |
Robert Fried
BRD | Director/Board Member | 66 | 2015-07-08 |
Steven Rubin
BRD | Director/Board Member | 65 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.14% | +4.33% | +9.88% | +31.73% | 47.97B | |
| -1.69% | +1.48% | +53.02% | +33.59% | 44.5B | |
| +2.56% | +7.34% | +382.17% | +594.81% | 43.93B | |
| +0.24% | +2.85% | +9.78% | +89.54% | 41.03B | |
| -0.62% | -1.11% | +4.70% | +46.02% | 29.85B | |
| -0.28% | +1.07% | +26.83% | +152.91% | 17.27B | |
| -0.46% | +1.20% | +26.78% | +41.32% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| +3.37% | +9.21% | +9.93% | - | 15.34B | |
| Average | +0.09% | +2.35% | +65.39% | +141.42% | 30B | |
| Weighted average by Cap. | +0.11% | +2.86% | +83.03% | +156.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 133M 117M 110M 101M 188M 12.76B 190M 1.32B 511M 6.52B 500M 489M 20.95B | 155M 136M 129M 117M 220M 14.89B 221M 1.54B 597M 7.6B 583M 571M 24.44B |
| Net income | 10.88M 9.55M 9.02M 8.22M 15.39M 1.04B 15.5M 108M 41.81M 533M 40.87M 39.98M 1.71B | 12.82M 11.25M 10.63M 9.68M 18.13M 1.23B 18.26M 127M 49.25M 628M 48.14M 47.1M 2.02B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NAGE Stock
- CDXC Stock
Select your edition
All financial news and data tailored to specific country editions
